[Development and functional verification of CAR-T cells targeting CLL-1]

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Acute myeloid leukemia (AML) remains a challenging hematologic malignancy with limited treatment options.
• CLL-1 is a cell surface antigen expressed on AML cells, making it a potential therapeutic target.

Purpose of the Study:

• To develop and validate chimeric antigen receptor T-cells (CAR-T) targeting the CLL-1 antigen for AML treatment.
• To assess the in vitro and in vivo efficacy of these engineered T-cells.

Main Methods:

• Flow cytometry was used to confirm CLL-1 expression in AML cell lines and primary samples.
• A lentiviral vector encoding a CLL-1 specific CAR was constructed and used to engineer T-cells.
• In vitro cytotoxicity assays and in vivo xenograft mouse models were employed to evaluate CAR-T cell function.

Main Results:

• CLL-1 expression was confirmed in AML cell lines and primary cells.
• Engineered CAR-T cells demonstrated specific and potent killing of CLL-1 positive AML cells in vitro.
• In vivo studies showed that CLL-1 CAR-T cells significantly inhibited tumor growth and prolonged survival in an AML xenograft mouse model.

Conclusions:

• Successful development of CLL-1-targeting CAR-T cells with significant anti-leukemic activity.
• These findings support the potential of CLL-1 CAR-T therapy as a novel treatment strategy for AML.